To prevent losing top scientific talent to administrative roles, the "Venture Catalyst" model pairs a scientist-founder with a dedicated business team. This allows the scientist to remain in the lab, focused on research, while the experienced partners handle finance, legal, and daily management.

Top VCs are reviving the early, hands-on model of pioneers like Arthur Rock. Instead of just investing, firms are co-designing new labs from scratch, providing compute, capital, and commercial guidance. This "company creation" approach is viable again as capital is no longer the primary bottleneck for ambitious, frontier-tech ideas.

WonderCo first maps a target market to find an exceptional company to back. They only choose to incubate a new company from scratch if their deep search reveals no existing "rocket" to provide fuel for, ensuring they build from a position of unique market insight.

Unlike venture creation firms that generate ideas internally, Curie.bio operates on a 'Freedom for Founders' principle. It believes the best ideas come from external innovators and its role is to augment them with capital-efficient support, fractional expertise, and operational help to translate those ideas into companies.

The biotech venture model is built on syndication, not competition. As a drug progresses, capital requirements balloon to hundreds of millions for late-stage trials, far exceeding any single VC's capacity. This structural reality forces firms to co-invest and partner throughout a company's lifecycle.

Backed by Aion Labs, a studio funded by competitors like Pfizer and Merck, DenovAI was co-created to solve a pre-validated industry challenge. This unique model provided deep R&D insights and a built-in customer base, ensuring its technology addressed real-world pharma needs from day one.

The CEO's team previously developed Zorampic, which failed commercially due to low efficacy and a kidney toxicity warning. This firsthand experience provided a precise roadmap for their next venture: finding a molecule that was significantly more potent and demonstrably free of the same renal safety liabilities.

ProPhet was founded through Ion Labs, a venture studio created by AstraZeneca, Merck, Pfizer, and Teva. This model allows established pharmaceutical giants to identify acute internal challenges and recruit external talent to build dedicated startups aimed at solving them.

Venture capital is shifting towards creating new companies from multiple de-risked assets acquired from large pharma. Bain's $300M investment to build a company around five BMS assets, led by a proven CEO, exemplifies this strategy. It mirrors previous successes like SpringWorks and minimizes single-asset failure risk.